J Korean Ophthalmol Soc > Volume 49(6); 2008 > Article
Journal of the Korean Ophthalmological Society 2008;49(6):1007-1012.
DOI: https://doi.org/10.3341/jkos.2008.49.6.1007    Published online June 15, 2008.
A Case of Retiserttrade mark Implant for Chronic Behcet's Panuveitis.
Eun Ji Lee, Hyeong Gon Yu
1Department of Ophthalmology, Seoul National University College of Medicine, Seoul, Korea. hgonyu@snu.ac.kr
2Research Center for Sensory Organs in Seoul National University Medical Research Center, Seoul, Korea.
3Research Center for Rheumatology in Seoul National University Medical Research Center, Seoul, Korea.
레티서트 안구내삽입술에 의한 만성 베체트 전체포도막염의 치험 1예
이은지1ㆍ유형곤1,2,3
Department of Ophthalmology, Seoul National University College of Medicine1, Seoul, Korea, / Research Center for Sensory Organs in Seoul National University Medical Research Center2, Seoul, Korea / Research Center for Rheumatology in Seoul National University Medical Research Center3, Seoul, Korea
Abstract
PURPOSE
Retisert(TM) (fluocinolone acetonide implant) has recently been approved for clinical use in patients with noninfectious posterior uveitis. We report a patient with intractable chronic Behcet's panuveitis who underwent Retisert(TM) implantation and showed a favorable outcome. METHODS: A 30-year-old male affected with intractable Behcet's uveitis of both eyes for over one year which did not respond to oral steroids and immunosuppressants; subcutaneous interferon injection caused undesirable side effects such as impotency and pyrexia. Initial visual acuities were 20/1000 in the right eye and 20/100 in the left eye, and both eyes showed severe panuveitis with posterior subcapsular cataract, especially in the right eye. The subtenon triamcinolone injection was performed in the right eye, which was only effective to anterior uveitis, and Retisert(TM) was implanted in the right eye after the cataract operation. Two months later the visual acuity increased to 20/25, and the inflammation was totally controlled. There were no ocular or systemic adverse events. CONCLUSIONS: Retiserttrade mark is a fast, effective, and safe treatment for chronic, non.infectious posterior uveitis.
Key Words: Fluocinolone acetonide;Retisert;Uveitis


ABOUT
BROWSE ARTICLES
EDITORIAL POLICY
FOR CONTRIBUTORS
Editorial Office
SKY 1004 Building #701
50-1 Jungnim-ro, Jung-gu, Seoul 04508, Korea
Tel: +82-2-583-6520    Fax: +82-2-583-6521    E-mail: kos08@ophthalmology.org                

Copyright © 2024 by Korean Ophthalmological Society.

Developed in M2PI

Close layer
prev next